ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Compare
Equity
Direct
Sector - Healthcare
NAV: ₹ 32.41 as on 22-04-2024
Fund Performance
zero opening, trading, fund transfer fee
2286 people have invested ₹ 1.5Cr in ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth in the last three months

Mutual Fund Insights

Insights icon
Over the last 6 months, this fund has experienced a 13.7% growth in AUM moving from 3.31K Cr to 3.77K Cr.
Insights icon
In the last 5 years, DSP Healthcare Fund Direct Growth has given 27.18% return, outperforming this fund by 1.92% per annum.
Insights icon
In the last 1 year, this fund has outperformed all funds in its category.
Insights icon
Over the last 6 months, this fund has decreased expense ratio by 14.0% moving from 1.21 to 1.04.
Insights icon
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 18.83% return, outperforming this fund by 0.23% per annum.
Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.04% which is lower than the category average expense ratio of 1.42%.

INDmoney Rank of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Powered by IND quant engine
IND ranking is not available for this fund.

Pros

5Y returns in the top 25% of the category
3Y returns in the top 25% of the category
Larger AUM within category

Cons

No bad points found for this fund.

About the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund. This fund was started on 12 July, 2018. The fund is managed by Dharmesh Kakkad. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has ₹3772 Cr worth of assets under management (AUM) as on Mar 2024 and is more than category average.
  2. The fund has an expense ratio 1.

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Overview

Expense ratio
Expense ratio
1.04%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹3772 Cr
Inception Date
Inception Date
12 July, 2018
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹100
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
49.46%

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Distribution as on (31-Mar-24)

  • Equity 98.7%

  • Debt & Cash 1.3%

Size breakup

Large cap
47.5%
Mid cap
28.4%
Small cap
22.9%
Sector Allocation

Mar'24

Feb'24

Jan'24

Health
90.7%
Basic Materials
4.9%
Financial Services
4.4%

Top Holdings of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth as on (31-Mar-24)

  • Equity

Equity Holdings45

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth: Monthly Changes Updates

All changes are between Jan'24 and Mar'24
Fund Performance
Mar'24
Feb'24
Jan'24
Fund Returns
0.50%
3.93%
6.94%
Nifty 500
-0.47%
1.58%
1.71%
  • This fund’s returns stands at 0.50% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.47% as on Mar'24
  • This fund outperformed Nifty 500 by 0.96% in Mar'24
AUM Change
Parameters
Mar'24
Feb'24
Jan'24
AUM
₹ 3.8K Cr
₹ 3.7K Cr
₹ 3.6K Cr
  • AUM of the fund stands at 3.8K Cr as of Mar'24
  • AUM increased by 77.5 Cr between Mar'24 and Feb'24
Fund Portfolio Changes

Gainers & Losers in ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth portfolio Returns for the month of Mar

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Fund Manager

Dharmesh Kakkad
Dharmesh Kakkad
Fund Manager of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth, since 2 May 2020

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 22.39% since inception which is more than its category average return of 19.81%
Fund Allocations

Fund Allocations

This fund has an allocation of 98.7% in Equity, 0% in Debt and 1.3% in Cash related instruments
AUM size ₹3772 Cr

AUM size ₹3772 Cr

This fund has AUM of ₹3772 Cr which is more than its category average of ₹ 1652 Cr
Expense Ratio 1.04%

Expense Ratio 1.04%

This fund has an expense ratio of 1.04% which is less than its category average expense ratio of 1.45%

Frequently Asked Questions

The current NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is ₹32.41 as on 22-Apr-2024.
Existing (Absolute + CAGR) as on 22-Apr-2024.
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
3.05%
3.05%
6 Month Returns
24.61%
24.61%
1 Year Returns
57.12%
57.12%
3 Years Returns
66.84%
18.6%
5 Years Returns
208.36%
25.26%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.04% as on March 2024
₹3772 Cr as on March 2024
Sun Pharmaceuticals Industries Ltd(15.24%), Dr Reddy's Laboratories Ltd(7.19%), Divi's Laboratories Ltd(6.68%), Aurobindo Pharma Ltd(6.56%), Apollo Hospitals Enterprise Ltd(6.45%) as on March 2024
Health(89.48%), Basic Materials(4.84%), Financial Services(4.38%) as on March 2024
The alpha ratio for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
5.52
3.54
5.27
As on March 2024
The alpha for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
0.9
0.88
0.93
As on March 2024
The Beta for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
3.26
1.05
1.04
As on March 2024
The sharpe ratio for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
13.56
14.68
18.96
As on March 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 2.02 as on March 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.65 as on March 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Dharmesh Kakkad is the fund manager of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
The Exit load of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is 1%